Advertisement

AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis

      Abstract

      The use of human albumin is common in hepatology since international scientific societies support its administration to treat or prevent severe complications of cirrhosis, such as the prevention of post-paracentesis circulatory dysfunction after large-volume paracentesis and renal failure induced by spontaneous bacterial peritonitis, and the treatment of hepatorenal syndrome in association with vasoconstrictors. However, these indications are often disregarded, mainly because the high cost of human albumin leads health authorities and hospital administrations to restrict its use. On the other hand, physicians often prescribe human albumin in patients with advanced cirrhosis for indications that are not supported by solid scientific evidence and/or are still under investigation in clinical trials.
      In order to implement appropriate prescription of human albumin and to avoid its futile use, the Italian Association for the Study of the Liver (AISF) and the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) nominated a panel of experts, who reviewed the available clinical literature and produced practical clinical recommendations for the use of human albumin in patients with cirrhosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • European Association for the Study of the Liver
        EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
        Journal of Hepatology. 2010; 53: 397-417
        • Runyon B.A.
        Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.
        Hepatology. 2013; 57: 1651-1653
      1. The GRADE system. www.gradeworkinggroup.org/.

        • Fanali G.
        • di Masi A.
        • Trezza V.
        • et al.
        Human serum albumin: from bench to bedside.
        Molecular Aspects of Medicine. 2012; 33: 209-290
        • Garcia-Martinez R.
        • Caraceni P.
        • Bernardi M.
        • et al.
        Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications.
        Hepatology. 2013; 58: 1836-1846
        • Arroyo V.
        • García-Martinez R.
        • Salvatella X.
        Human serum albumin, systemic inflammation, and cirrhosis.
        Journal of Hepatology. 2014; 61: 396-407
        • Domenicali M.
        • Baldassarre M.
        • Giannone F.A.
        • et al.
        Post-transcriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis.
        Hepatology. 2014; 60: 1851-1860
        • Jalan R.
        • Schnurr K.
        • Mookerjee R.P.
        • et al.
        Alteration in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality.
        Hepatology. 2009; 50: 555-564
        • Møller S.
        • Henriksen J.H.
        Cardiovascular complications of cirrhosis.
        Postgraduate Medical Journal. 2009; 85: 44-54
        • Bernardi M.
        • Moreau R.
        • Angeli P.
        • et al.
        Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis.
        Journal of Hepatology. 2015; 63: 1272-1284
        • Moreau R.
        • Jalan R.
        • Gines P.
        • et al.
        Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.
        Gastroenterology. 2013; 144: 1426-1437
        • Fernández J.
        • Monteagudo J.
        • Bargallo X.
        • et al.
        A randomized unblinded pilot study comparing albumin vs. hydroxyethyl starch in spontaneous bacterial peritonitis.
        Hepatology. 2005; 42: 627-634
        • Bortoluzzi A.
        • Ceolotto G.
        • Gola E.
        • et al.
        Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms.
        Hepatology. 2013; 57: 266-276
        • Ginès P.
        • Tito L.V.
        • Arroyo V.
        • et al.
        Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
        Gastroenterology. 1988; 94: 1493-1502
        • Ginès A.
        • Fernandez-Esparrach G.
        • Monescillo A.
        • et al.
        Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis.
        Gastroenterology. 1996; 111: 1002-1010
        • Solà R.
        • Vila M.C.
        • Andreu M.
        • et al.
        Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study.
        Journal of Hepatology. 1994; 20: 282-288
        • Panos M.Z.
        • Moore K.
        • Vlavianos P.
        • et al.
        Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size.
        Hepatology. 1990; 11: 662-667
        • Pozzi M.
        • Osculati G.
        • Boari G.
        • et al.
        Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites.
        Gastroenterology. 1994; 106: 709-719
        • Ruiz del Arbol L.
        • Monescillo A.
        • Jimenez W.
        • et al.
        Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis.
        Gastroenterology. 1997; 113: 579-586
        • Planas R.
        • Ginès P.
        • Arroyo V.
        • et al.
        Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study.
        Gastroenterology. 1990; 99: 1736-1744
        • Salerno F.
        • Badalamenti S.
        • Lorenzano E.
        • et al.
        Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites.
        Hepatology. 1991; 13: 707-713
        • Fassio E.
        • Terg R.
        • Landeira G.
        • et al.
        Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study.
        Journal of Hepatology. 1992; 14: 310-316
        • Altman C.
        • Bernard B.
        • Roulot D.
        • et al.
        Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis.
        European Journal of Gastroenterology and Hepatology. 1998; 10: 5-10
        • García-Compeán D.
        • Blanc P.
        • Larrey D.
        • et al.
        Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial.
        Annals of Hepatology. 2002; 1: 29-35
        • Sola-Vera J.
        • Miñana J.
        • Ricart E.
        • et al.
        Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.
        Hepatology. 2003; 37: 1147-1153
        • Abdel-Khalek E.E.
        • Arif S.E.
        Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis.
        Arab Journal of Gastroenterology. 2010; 11: 24-29
        • Brunkhorst F.M.
        • Angel C.
        • Bloos F.
        • et al.
        Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
        New England Journal of Medicine. 2008; 358: 125-139
        • Christidis C.
        • Mal F.
        • Ramos J.
        • et al.
        Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions.
        Journal of Hepatology. 2001; 35: 726-732
        • Moreau R.
        • Asselah T.
        • Condat B.
        • et al.
        Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
        Gut. 2002; 50: 90-94
        • Singh V.
        • Kumar B.
        • Nain C.K.
        • et al.
        Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study.
        Journal of Internal Medicine. 2006; 260: 62-68
        • Singh V.
        • Kumar R.
        • Nain C.K.
        • et al.
        Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
        Journal of Gastroenterology and Hepatology. 2006; 21: 303-307
        • Appenrodt B.
        • Wolf A.
        • Grunhage F.
        • et al.
        Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
        Liver International. 2008; 28: 1019-1025
        • Singh V.
        • Dheerendra P.C.
        • Singh B.
        • et al.
        Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.
        American Journal of Gastroenterology. 2008; 103: 1399-1405
        • Moreau R.
        • Valla D.C.
        • Durand-Zaleski I.
        • et al.
        Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail.
        Liver International. 2006; 26: 46-54
        • Bernardi M.
        • Caraceni P.
        • Navickis R.J.
        • et al.
        Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.
        Hepatology. 2012; 55: 1172-1181
        • Alessandria C.
        • Elia C.
        • Mezzabotta
        • et al.
        Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.
        Digestive and Liver Disease. 2011; 43: 881-886
        • Rimola A.
        • García-Tsao G.
        • Navasa M.
        • et al.
        Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club.
        Journal of Hepatology. 2000; 32: 142-153
        • Follo A.
        • Llovet J.M.
        • Navasa M.
        • et al.
        Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.
        Hepatology. 1994; 20: 1495-1501
        • Tandon P.
        • Garcia-Tsao G.
        Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis.
        Clinical Gastroenterology and Hepatology. 2011; 9: 260-265
        • Ruiz-del-Arbol L.
        • Urman J.
        • Fernández J.
        • et al.
        Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.
        Hepatology. 2003; 38: 1210-1218
        • Sort P.
        • Navasa M.
        • Arroyo V.
        • et al.
        Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
        New England Journal of Medicine. 1999; 341: 403-409
        • Sigal S.H.
        • Stanca C.M.
        • Fernandez J.
        • et al.
        Restricted use of albumin for spontaneous bacterial peritonitis.
        Gut. 2007; 56: 597-599
        • Poca M.
        • Concepción M.
        • Casas M.
        • et al.
        Role of albumin treatment in patients with spontaneous bacterial peritonitis.
        Clinical Gastroenterology and Hepatology. 2012; 10: 309-315
        • De Araujo A.
        • De Barros Lopes A.
        • Rossi G.
        • et al.
        Low-dose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment?.
        Gut. 2012; 61: 1371-1372
        • Salerno F.
        • Navickis R.J.
        • Wilkes M.M.
        Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials.
        Clinical Gastroenterology and Hepatology. 2013; 11: 123-130
        • Arroyo V.
        • Ginès P.
        • Gerbes A.L.
        • et al.
        Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.
        Hepatology. 1996; 23: 164-176
        • Salerno F.
        • Gerbes A.
        • Ginès P.
        • et al.
        Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.
        Gut. 2007; 56: 1310-1318
        • Angeli P.
        • Gines P.
        • Wong F.
        • et al.
        Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.
        Gut. 2015; 64: 531-537
        • Ginès P.
        • Schrier R.W.
        Renal failure in cirrhosis.
        New England Journal of Medicine. 2009; 361: 1279-1290
        • Moreau R.
        • Lebrec D.
        The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
        Hepatology. 2006; 43: 385-394
        • Ortega R.
        • Ginès P.
        • Uriz J.
        • et al.
        Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
        Hepatology. 2002; 36: 941-948
        • Martín-Llahí M.
        • Pépin M.-N.
        • Guevara M.
        • et al.
        Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
        Gastroenterology. 2008; 134: 1352-1359
        • Sanyal A.J.
        • Boyer T.
        • Garcia-Tsao G.
        • et al.
        A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
        Gastroenterology. 2008; 134: 1360-1368
        • Neri S.
        • Pulvirenti D.
        • Malaguarnera M.
        • et al.
        Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
        Digestive Diseases and Sciences. 2008; 53: 830-835
        • Solanki P.
        • Chawla A.
        • Garg R.
        • et al.
        Beneficial effects of terlipressin in hepatorenal syndrome: a prospective randomized placebo-controlled clinical trial.
        Journal of Gastroenterology and Hepatology. 2003; 18: 152-156
        • Yang Y.Z.
        • Dan Z.L.
        • Liu N.Z.
        • et al.
        Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome.
        Journal of Internal Medicine. 2001; 7: 123-125
        • Salerno F.
        • Cazzaniga M.
        • Merli M.
        • et al.
        Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
        Journal of Hepatology. 2011; 55: 1241-1248
        • Rodríguez E.
        • Elia C.
        • Solà E.
        • et al.
        Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
        Journal of Hepatology. 2014; 60: 955-961
        • Gluud L.L.
        • Christensen K.
        • Christensen E.
        • et al.
        Terlipressin for hepatorenal syndrome.
        Cochrane Database of Systematic Review. 2012; 9: CD005162
        • Alessandria C.
        • Ottobrelli A.
        • Debernardi-Venon W.
        • et al.
        Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
        Journal of Hepatology. 2007; 47: 499-505
        • Singh V.
        • Ghosh S.
        • Singh B.
        • et al.
        Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
        Journal of Hepatology. 2012; 56: 1293-1298
        • Cavallin M.
        • Kamath P.S.
        • Merli M.
        • et al.
        Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.
        Hepatology. 2015; 62: 567-574
        • Alessandria C.
        • Venon W.D.
        • Marzano A.
        • et al.
        Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
        European Journal of Gastroenterology and Hepatology. 2002; 14: 1363-1368
        • Ghosh S.
        • Choudhary N.S.
        • Sharma A.K.
        • et al.
        Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
        Liver International. 2013; 33: 1187-1193
        • Moore K.P.
        • Wong F.
        • Gines P.
        • et al.
        The management of ascites in cirrhosis: report on the Consensus Conference of the International Ascites Club.
        Hepatology. 2003; 38: 258-266
        • Gines P.
        • Cardenas A.
        • Arroyo V.
        • et al.
        Management of cirrhosis and ascites.
        New England Journal of Medicine. 2004; 350: 1646-1654
        • Arroyo V.
        • Gines P.
        • Gerbes A.L.
        • et al.
        Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
        Hepatology. 1996; 23: 164-176
        • Gentilini P.
        • Casini-Raggi V.
        • Di Fiore G.
        • et al.
        Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
        Journal of Hepatology. 1999; 30: 639-645
        • Romanelli R.G.
        • La Villa G.
        • Barletta G.
        • et al.
        Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.
        World Journal of Gastroenterology. 2006; 12: 1403-1407
        • Bernardi M.
        • Riggio O.
        • Angeli P.
        • et al.
        Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: the interim analysis of the ANSWER study.
        Digestive and Liver Disease. 2015; 47: e6
        • Ginès P.
        • Berl T.
        • Bernardi M.
        • et al.
        Hyponatremia in cirrhosis: from pathogenesis to treatment.
        Hepatology. 1998; 28: 851-864
        • Angeli P.
        • Wong F.
        • Watson H.
        • et al.
        Hyponatremia in cirrhosis: results of a patient population survey.
        Hepatology. 2006; 44: 1535-1542
        • Kim W.R.
        • Biggins S.W.
        • Krmers W.K.
        • et al.
        Hyponatremia and mortality among patients on the liver transplant waiting list.
        New England Journal of Medicine. 2008; 359: 1018-1026
        • Guevara M.
        • Baccaro M.E.
        • Ríos J.
        • et al.
        Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration.
        Liver International. 2010; 30: 1137-1142
        • Yun B.C.
        • Kim W.R.
        • Benson J.T.
        • et al.
        Impact of pretransplant hyponatremia on outcome following liver transplantation.
        Hepatology. 2009; 49: 1610-1615
        • McCormick P.A.
        • Mistry P.
        • Kaye G.
        • et al.
        Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites.
        Gut. 1990; 31: 204-207
        • Jalan R.
        • Mookerjee R.
        • Cheshire L.
        • et al.
        Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trail.
        Journal of Hepatology. 2007; 46 ([Abstract]): 232A
        • Terra C.
        • Guevara M.
        • Torre A.
        • et al.
        Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score.
        Gastroenterology. 2005; 129: 1944-1953
        • Fasolato S.
        • Angeli P.
        • Dallagnese L.
        • et al.
        Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features.
        Hepatology. 2007; 45: 223-229
        • Guevara M.
        • Terra C.
        • Nazar A.
        • et al.
        Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study.
        Journal of Hepatology. 2013; 57: 759-765
        • Thévenot T.
        • Bureau C.
        • Oberti F.
        • et al.
        Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial.
        Journal of Hepatology. 2015; 62: 822-830
        • Jones A.E.
        • Puskarich M.A.
        The Surviving Sepsis Campaign guidelines 2012: update for emergency physicians.
        Annals of Emergency Medicine. 2014; 63: 35-47
        • SAFE Study Investigators
        • Finfer S.
        • McEvoy S.
        • et al.
        Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis.
        Intensive Care Medicine. 2011; 37: 86-96
        • Delaney A.
        • Dan A.
        • McCaffrey J.
        • et al.
        The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis.
        Critical Care Medicine. 2011; 39: 386-391
        • Caironi P.
        • Tognoni G.
        • Masson S.
        • et al.
        Albumin replacement in patients with severe sepsis or septic shock.
        New England Journal of Medicine. 2014; 370: 1412-1421
        • Vilstrup H.
        • Amodio P.
        • Bajaj J.
        • et al.
        Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.
        Hepatology. 2014; 60: 715-735
        • Simón-Talero M.
        • García-Martínez R.
        • Torrens M.
        • et al.
        Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.
        Journal of Hepatology. 2013; 59: 1184-1192
        • Riggio O.
        • Nardelli S.
        • Pasquale C.
        • et al.
        No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
        Metabolic Brain Disease. 2015; ([Epub ahead of print])
        • Vargas E.
        • De Miguel V.
        • Portolés A.
        • et al.
        Use of albumin in two Spanish university hospitals.
        European Journal of Clinical Pharmacology. 1997; 52: 465-470
        • Debrix I.
        • Combeau D.
        • Stephan F.
        • et al.
        Clinical practice guidelines for the use of albumin: results of a drug use evaluation in a Paris hospital. Tenon Hospital Paris.
        Pharmacy World and Science. 1999; 21: 11-16
        • Tarín Remohí M.J.
        • Sánchez Arcos A.
        • Santos Ramos B.
        • et al.
        Costs related to inappropriate use of albumin in Spain.
        Annals of Pharmacotherapy. 2000; 34: 1198-1205
        • Tanzi M.
        • Gardner M.
        • Megellas M.
        • et al.
        Evaluation of the appropriate use of albumin in adult and pediatric patients.
        American Journal of Health-System Pharmacy. 2003; 60: 1330-1335
        • Calizzani G.
        • Lanzoni M.
        • Candura F.
        • et al.
        Analisi della domanda dei principali medicinali plasmaderivati in Italia. Anni 2007–2011.
        Istituto Superiore di Sanità, Roma2012 (Rapporti ISTISAN 12/53. Available at: http://www.iss.it/binary/publ/cont/dodici53web.pdf [accessed 31.10.13])
        • Lanzoni M.
        • Biffoli C.
        • Candura F.
        • et al.
        Plasma-derived medicinal products in Italy: information sources and flows.
        Blood Transfusion. 2013; 11: 3-7
        • Vaglio S.
        • Calizzani G.
        • Lanzoni M.
        • et al.
        The demand for human albumin in Italy.
        Blood Transfusion. 2013; 11: 26-32
        • Vaglio S.
        • Calizzani G.
        • Grazzini G.
        • et al.
        Italian albumin usage (or misusage?.).
        European Journal of Internal Medicine. 2014; 25: e31-e32
        • Mirici-Cappa F.
        • Caraceni P.
        • Domenicali M.
        • et al.
        How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure.
        World Journal of Gastroenterology. 2011; 17: 3479-3486